1 March 2005 in Biochemical and Biophysical Research Communications
1 July 2014 in Mitochondrion
1 December 2016 in Journal of Pediatric Gastroenterology and Nutrition
Background: Mitochondrial liver disease (MLD), and in particular mitochondrial DNA (mtDNA) depletion syndrome (MDS) is an important cause of acute liver failure (ALF) in infancy. Early and accurate diagnosis is important because liver transplantation (LT) is often contraindicated. It is unclear which methods are the best to diagnose MLD in the setting of ALF.Objective: The aim of the study was to determine the incidence of MLD in children younger than 2 years with ALF and the utility of routine investigations to detect MLD.Methods: Thirty‐nine consecutive infants with ALF were admitted to a single unit from 2009 to 2011. All were extensively investigated using an established protocol. Genes implicated in mitochondrial DNA depletion syndrome were sequenced in all cases and tissue mtDNA copy number measured where available.Results: Five infants (17%) had genetically proven MLD: DGUOK (n = 2), POLG (n = 2), and MPV17 (1). Four of these died, whereas 1 recovered. Two had normal muscle mtDNA copy number and 3 had normal muscle respiratory chain enzymes. An additional 8 children had low hepatic mtDNA copy number but pathogenic mutations were not detected. One of these developed fatal multisystemic disease after LT, whereas 5 who survived remain well without evidence of multisystemic disease up to 6 years later. Magnetic resonance spectroscopy did not distinguish between those with and without MLD.Conclusions: Low liver mtDNA copy number may be a secondary phenomenon in ALF.Screening for mtDNA maintenance gene mutations may be the most efficient way to confirm MLD in ALF in the first 2 years of life.
1 December 2000 in Developmental Neuroscience
The effect of aglycaemic hypoxia (AH) on the activity of the mitochondrial respiratory chain complexes was measured in superfused neonatal cortical brain slices. After 30 min AH, there were no significant changes in the activities of complex I, II–III and IV or citrate synthase compared to controls. Following 30 min AH and a 30-min reperfusion period (with oxygen and glucose), the activities of complex II–III and complex IV were significantly reduced (by 25 and 17%, respectively). These reductions in enzyme activity were not abrogated by removing external calcium prior to and throughout AH, but could be reversed by the presence of the nitric oxide (NO) synthase inhibitor Nω-nitro-L-arginine during these periods. These data suggest that NO or an NO-derived species is involved in the decreases in mitochondrial enzyme activities observed after AH
2 October 2018 in British Journal of Neuroscience Nursing
Organophosphate (OP) poisoning can occur in acute and chronic forms. In developing countries, both forms are common, and represent a major cause of morbidity and mortality. In the UK, organophosphate poisoning is most likely to be encountered in chronic form, with sheep farmers the section of the population at greatest risk. The problem of poisoning in sheep farmers caused by exposure to organophosphate-based sheep dips has become increasingly apparent. Symptoms include fatigue, muscle pain and neurological problems. There is no specific treatment for this condition. OP toxicity is classically associated with inhibition of acetylcholinesterase enzymes involved in the process of neurotransmission. However, there is evidence that OP poisoning can also cause mitochondrial dysfunction, compromised cellular energy supply, oxidative stress and inflammation. Symptoms of sheep dip poisoning correspond with those known to result from depletion of coenzyme Q10 (CoQ10), a vitamin-like substance with a key role in cellular energy generation within mitochondria, as well as antioxidant and anti-inflammatory action. The authors have therefore reviewed evidence that oral supplementation with CoQ10 may provide effective symptomatic relief for farmers suffering from OP sheep dip poisoning. Evidence in support of the above is presented for: (a) OP-induced mitochondrial dysfunction; (b) beneficial effects of CoQ10 administration following OP exposure in relevant animal models; and (c) evidence from clinical studies in human subjects. The dosage of CoQ10 proposed (100 mg three times daily) is based on that required to raise blood levels to at least 3 μg/mL, which has been shown to be a requirement to effectively counter CoQ10 depletion in other disorders, particularly heart disease. It is important to note that a CoQ10 supplement with appropriate documented bioavailability should be used, since poor bioavailability may have been responsible for the failure of some previous studies. The safety of CoQ10 supplementation has been confirmed in more than 200 randomised controlled clinical trial studies on a wide range of disorders. In addition to the above, because of the increased risk of the use of OP compounds in terrorist-type poisoning incidents in the UK, a brief discussion on the management of acute OP poisoning is included.